Full Press Release Details
for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60th
American Society of Hematology Annual Meeting
--Three abstracts accepted, including
oral presentation on multiple myeloma clinical data--
- November 27, 2018 - Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company, today
reported that data from three abstracts-including an oral presentation-were accepted for presentation at the 60th American
Society of Hematology Annual Meeting (ASH 2018). The studies describe results achieved using
multi-tumor antigen specific T cells that were developed at the Baylor College of Medicine in the laboratories of Dr. Ann Leen
and Dr. Juan Vera, and exclusively licensed to Marker.
Among the highlights,
results from an ongoing Phase 1 study in patients with multiple myeloma will be reviewed
in an oral presentation by Premal Lulla, M.B.B.S., Assistant Professor of Medicine at the Center for Cell and Gene Therapy, Hematology-Oncology,
at the Baylor College of Medicine.
take place in San Diego, CA from December 1-4.
Oral Presentation Details:
Title: Safety and Efficacy of Multiantigen-Targeted
T Cells for Multiple Myeloma (Abstract # 1014)
Date: Monday, December 3, 2018
Time: 7:30 p.m. PST (San Diego Convention
Center, Ballroom 20D)
Poster Presentation Details:
Title: Targeting Lymphomas Using
Non-Engineered, Multi-Antigen Specific T Cells (Abstract #1685)
Date: Saturday, December 1, 2018
Presentation Time: 6:15 p.m. -
8:15 p.m. PST (San Diego Convention Center, Hall GH)
Title: Adoptive T-Cell Therapy for
Acute Lymphoblastic Leukemia Targeting Multiple Tumor Associated Antigens (Abstract #2693)
Date: Sunday, December 2, 2018
Presentation Time: 6:00 p.m. -
8:00 p.m. PST (San Diego Convention Center, Hall GH)
The presentations will contain results
beyond what are available in the abstracts on the ASH website.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage
immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological
malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered,
tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets.
Once infused into patients, this population of T cells attacks multiple tumor targets and activates the patient's immune
system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to
current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture,
(ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes
its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and
TCR-based therapies.
Marker is also advancing several innovative
peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha
program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials.
In parallel, we are developing a proprietary DNA expression technology named PolyStart to improve the ability of the cellular
immune system to recognize and destroy diseased cells.
For additional information, please call
toll free at (904) 862-6490 or visit: markertherapeutics.com.
To receive future press releases via email, please visit: https://markertherapeutics.com/email-alerts/.
Forward-Looking Statement Disclaimer
release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements
in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other
statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking
statements". Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: our research and development activities relating to our multi-tumor antigen
specific T cell therapies; our TPIV200 and TPIV100/110 programs and our PolyStart program;
the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment
of diseases; and, the timing and success of our clinical trials, as well as Multi-TAA T cell clinical trials conducted by Baylor
College of Medicine. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could
cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include,
but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available
through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
Marker Therapeutics, Inc.
(904) 862-6490 EXT. 102